JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Kodu・Aktsiate loetelu・Celsion Corp

Celsion Corp

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+484.7% upside

Celsion Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. apr 2026, 23:08 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 23:07 UTC

Tulu

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:20 UTC

Tulu

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. apr 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. apr 2026, 23:22 UTC

Tulu

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. apr 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. apr 2026, 22:52 UTC

Tulu

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. apr 2026, 22:33 UTC

Tulu

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. apr 2026, 22:32 UTC

Tulu

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. apr 2026, 22:24 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. apr 2026, 22:23 UTC

Omandamised, ülevõtmised, äriostud

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. apr 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. apr 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. apr 2026, 22:05 UTC

Tulu

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. apr 2026, 21:57 UTC

Tulu

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. apr 2026, 21:56 UTC

Tulu

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. apr 2026, 21:55 UTC

Tulu

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. apr 2026, 21:54 UTC

Tulu

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. apr 2026, 21:53 UTC

Tulu

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. apr 2026, 21:49 UTC

Tulu

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Võrdlus sarnastega

Hinnamuutus

Celsion Corp Prognoos

Hinnasiht

By TipRanks

484.7% tõus

12 kuu keskmine prognoos

Keskmine 15.67 USD 484.7%

Kõrge 25 USD

Madal 10 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Celsion Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Celsion Corp aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Ettevõttest Celsion Corp

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.